Stock Events

Stock Events

Oncoinvent ASA. 

kr0
0
-kr0-87.5% Tuesday 15:26

Statistics

Day High
0.01
Day Low
0
52W High
0.01
52W Low
0
Volume
13,463,934
Avg. Volume
-
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

Earnings

20AugExpected
Q2 2025
999
333
-333
-999
Expected EPS
N/A
Actual EPS
N/A

People Also Follow

This list is based on the watchlists of people on Stock Events who follow ONCIT.OL. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Incyte
INCY
Mkt Cap18.84B
Incyte Corporation focuses on the discovery, development, and commercialization of various therapeutics, including those in oncology, which competes with BerGenBio's cancer-focused pipeline.
AMGEN
AMGN
Mkt Cap185.74B
Amgen Inc. is a biotechnology company that develops and produces medicines in areas including oncology/hematology, competing directly with BerGenBio's cancer treatment developments.
Gilead Sciences
GILD
Mkt Cap161.85B
Gilead Sciences, Inc. is involved in the research, development, and commercialization of drugs in areas such as oncology, directly competing with BerGenBio's therapeutic areas.
Merck
MRK
Mkt Cap276.38B
Merck & Co., Inc. is a global healthcare company that produces pharmaceuticals across various areas, including cancer, making it a competitor to BerGenBio.
Bristol-Myers Squibb
BMY
Mkt Cap119.87B
Bristol-Myers Squibb Company offers biopharmaceutical products, including those for cancer treatment, competing with BerGenBio's oncology focus.
Novartis
NVS
Mkt Cap280.79B
Novartis AG engages in the research, development, manufacturing, and marketing of healthcare products, including oncology, which competes with BerGenBio's product range.
Pfizer
PFE
Mkt Cap153.59B
Pfizer Inc. is a research-based global biopharmaceutical company with a broad range of products including oncology treatments, competing with BerGenBio.
Roche
RHHBY
Mkt Cap332.61B
Roche Holding AG focuses on pharmaceuticals and diagnostics in oncology, among other areas, directly competing with BerGenBio's cancer therapies.
Astrazeneca
AZN
Mkt Cap294.17B
AstraZeneca PLC is a biopharmaceutical company focusing on the discovery, development, and commercialization of prescription medicines, including for cancer, competing with BerGenBio.
Lilly(Eli) &
LLY
Mkt Cap789.69B
Eli Lilly and Company is engaged in the discovery, development, manufacture, and sale of a range of pharmaceutical products, including those for cancer, making it a competitor to BerGenBio.

About

Oncoinvent ASA, a clinical stage company, develops radiopharmaceutical therapies against cancer. Its lead product candidate is Radspherin, an alpha-radiation therapy candidate for treating cancer that have spread to body cavities, including peritoneum in two phase 1/2a trials and one randomized phase 2 trial. The company is based in Oslo, Norway.
Show more...
CEO
Mr. Oystein Soug M.Sc
Employees
36
Country
Other
ISIN
NO0013674408

Listings

ST
SE
BGBIOO.ST
MU
DE
7BG.MU
STU
DE
7BG.STU
OL
NO
ONCIN.OL

0 Comments

Share your thoughts

FAQ

What is Oncoinvent ASA. stock price today?▼
The current price of ONCIT.OL is kr0 NOK — it has decreased by -87.5% in the past 24 hours. Watch Oncoinvent ASA. stock price performance more closely on the chart.
What is Oncoinvent ASA. stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Oncoinvent ASA. stocks are traded under the ticker ONCIT.OL.
How many employees does Oncoinvent ASA. have?▼
As of May 04, 2026, the company has 36 employees.
In which sector is Oncoinvent ASA. located?▼
Oncoinvent ASA. operates in the Other sector.
When did Oncoinvent ASA. complete a stock split?▼
Oncoinvent ASA. has not had any recent stock splits.
Where is Oncoinvent ASA. headquartered?▼
Oncoinvent ASA. is headquartered in Oslo, Other.